Ï㽶ÊÓƵ

Lisa Munter

Academic title(s): 

Associate Professor, Department of Pharmacology & Therapeutics

Lisa Munter
Contact Information
Address: 

Bellini Life Sciences Complex
3649 Promenade Sir William Osler, Room 136
Montreal, QC, H3G 0B1

Email address: 
lisa.munter [at] mcgill.ca
Phone: 
514-398-2159
Department: 
Pharmacology and Therapeutics
Area(s): 
Neurological Disorders
Structural biology
Degree(s): 

Dr. Lisa-Marie Munter obtained a Dr. rer. nat. degree in Biochemistry at the Freie Universität Berlin in 2007. Her postdoctoral years were spent at the University of Melbourne in the department of Pathology and the Freie Universität Berlin (2007-2012). She joined the department of Pharmacology at Ï㽶ÊÓƵ in August 2012.

Current research: 

My research interests focus around the molecular pathways leading to Alzheimer’s disease. Mutations in the amyloid precursor protein (APP) causatively link APP to Alzheimer’s disease, however, its physiological function is still incompletely understood. APP is cleaved by several proteases and we have identified a new, additional protease cleaving APP, i.e. the rhomboid-related protein 4 (RHBDL4). RHBDL4’s activity is regulated by cellular cholesterol levels, potentially linking this pathway to cholesterol as an established risk factor for Alzheimer’s disease. Furthermore, the cholesterol transporter apolipoprotein E variant 4 (ApoE4) is genetically causatively linked to Alzheimer’s disease, again an incompletely understood molecular pathway. My goals are to: 1) fully reveal the physiological function of APP utilizing the RHBDL4-mediated processing pathway, and 2) to understand cellular cholesterol distribution in the brain in relation to ApoE4 and other cholesterol-transporting proteins. My team utilizes appropriate cell culture and mouse models and a wide range of core facility tools available at McGill including mass spectrometry, fluorescent and electron microscopy, histology, FACS, the transgenic animal core, PET imaging and metabolomics. Our gained knowledge will inform us to develop new therapeutic strategies to prevent the onset of Alzheimer’s disease.

Selected publications: 

Back to top